Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gurney, H.
Right arrow Articles by Tindall, V. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gurney, H.
Right arrow Articles by Tindall, V. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 1:423-433, 1990
© 1990 European Society for Medical Oncology

research-article

Original article: Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma

H. Gurney1, D. Crowther1, H. Anderson1, D. Murphy1, J. Prendiville1, M. Ranson1, P. Mayor2, R. Swindell3, C. H. Buckley4 and V. R. Tindall5

1CRC Department of Medical Oncology, Christie Hospital Manchester, UK
2Department of Diagnostic Radiology, Christie Hospital Manchester, UK
3Department of Medical Statistics, Christie Hospital Manchester, UK
4University Department of Reproductive Pathology, St Mary's Hospital Manchester, UK
5University Department of Obstetrics and Gynaecology, St Mary's Hospital Manchester, UK

Correspondence to: Professor D. Crowther, Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, M20 9BX, UK

Eighty eight patients with FIGO stage Ilb/c (postoperative residual) or III/TV epithelial ovarian cancer were randomised to receive cycles of cyclophosphamide (600 mg/m2) with either iproplatin (240 mg/m2), cisplatin (100 mg/m2) or carboplatin (300 mg/m2). A total of six cycles were given at monthly intervals. Patients were well-balanced for major prognostic factors. There was no significant difference in overall response rate (iproplatin arm, 64.3%, cisplatin arm 72.7% and carboplatin arm 66.7%). There were more complete remissions on the carboplatin arm, 45.8% compared with 21.4% on iproplatin and 22.7% on cisplatin but the difference was not statistically significant (p=0.11). With a median follow up of 50 months the median survival for the iproplatin arm is 18 months, for the cisplatin arm 19 months and for the carboplatin arm 24 months (p=0.15). Toxicity was greatest with cisplatin and least with carboplatin. Myelotoxicity limited the dose delivery of iproplatin as measured by total dose, dose intensity and dose intensity product. Carboplatin is at least as effective and less toxic than cisplatin when used in conjunction with cyclophosphamide for the treatment of ovarian carcinoma, and this analogue has been selected for dose intensification studies in this tumour at the Christie Hospital.

ovarian carcinoma, cisplatin, carboplatin, CHIP


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.